Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical
References
- A. Vaillant, B. R. Pandit, C. Unakal, S. Vuma and P. E. Akpaka, A comprehensive review about the use of monoclonal antibodies in cancer therapy, Antibodies 14(2) (2025) Article ID 35 (25 pages); https://doi.org/10.3390/antib14020035
- K. Toledo-Stuardo, C. H. Ribeiro, F. González-Herrera, D. J. Matthies, M. S. Le Roy, C. Dietz-Vargas, Y. Latorre, I. Campos, Y. Guerra, S. Tello, V. Vásquez-Sáez, P. Novoa, N. Fehring, M. González, J. Rodríguez-Siza, G. Vásquez, P. Méndez, C. Altamirano and M. C. Molina, Therapeutic antibodies in oncology: An immunopharmacological overview, Cancer Immunol. Immunother. 73 (2024) Article ID 242 (22 pages); https://doi.org/10.1007/s00262-024-03814-2
- European Medicines Agency, EU/3/03/136 – Orphan Designation: Iodine (¹³¹I) Tositumomab for the Treatment of Follicular Lymphoma, EMA, Amsterdam, May 2015; https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-136; last access date January 11, 2026
- European Medicines Agency, Zevalin: EPAR – Medicine Overview, EMA, Amsterdam 2011; https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin; last access date January 11, 2026
- S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini, M. V. Mateos, S. Kumar, J. Hillengass, E. Kastritis, P. Richardson, O. Landgren, B. Paiva, A. Dispenzieri, B. Weiss, X. Leleu, S. Zweegman, S. Lonial, L. Rosinol, E. Zamagni, S. V. Rajkumar, J. San Miguel and K. C. Anderson, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol. 15 (2014) e538–e548; https://doi.org/10.1016/S1470-2045(14)70442-5
- J. H. Yi, D. H. Yoon, S. Park, H. K. Kim, J. S. Kim, S. S. Yoon, K. Kim, C. K. Min, S. J. Lee, S. J. Lee, K. H. Lee, J. H. Lee, D. H. Yang, J. J. Lee, H. J. Kim and J. J. Lee, Real-world outcomes of SLiM-only multiple myeloma: Korean multicenter retrospective analysis (KMM2401 study), Ann. Hematol. 105 (2026) Article ID 93 (8 pages); https://doi.org/10.1007/s00277-026-06851-2
- K. Ghaffari, A. Moradi Hasan-Abad, M. Etedali, S. Alizadeh and A. Ghasemi, Hematologic malignancies and an overview of emerging therapies for hematologic malignancies: A systematic review, Cancer Treat. Res. Commun. 46 (2026) Article ID 101074 (16 pages); https://doi.org/10.1016/j.ctarc.2025.101074
- M. C. Palanca-Wessels and O. W. Press, Advances in the treatment of hematologic malignancies using immunoconjugates, Blood 123(15) (2014) 2293–2301; https://doi.org/10.1182/blood-2013-10-492223
- European Medicines Agency, Darzalex (daratumumab) – EPAR – Medicine Overview, EMA, Amsterdam 2025; https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex; last access date December 1, 2025
- U. S. Food and Drug Administration, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) Injection, for Subcutaneous Use – Prescribing Information, US FDA, Silver Spring 2020; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf; last access date January 11, 2026
- European Medicines Agency, Sarclisa – EPAR – Medicine Overview, EMA, Amsterdam 2025; https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa; last access date January 11, 2026
- M. de Weers, Y.-T. Tai, M. S. van der Veer, J. M. Bakker, T. Vink, D. C. Jacobs, L. A Oomen, M. Peipp, T. Valerius, J. W. Slootstra, T. Mutis, W. K. Bleeker, K. C. Anderson, H. M. Lokhorst, J. G. J. van de Winkel, P. W. H. I. Parrenl, Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors, J. Immunol. 186 (2011) 1840–1848; https://doi.org/10.4049/jimmunol.1003032
- S. Yadav, S. Gundeti, A. Bhave, U. Deb, J. Dixit and K. Mishra, Role of daratumumab in the frontline management of multiple myeloma: A narrative review, Expert Rev. Hematol. 16(10) (2023) 743–760; https://doi.org/10.1080/17474086.2023.2246651
- C. Wang, Z. Xu, M. Jiang, Y. Chen and Y. Lan, Efficacy and safety of isatuximab combination therapy in multiple myeloma: A meta-analysis of randomized controlled trials, Cancers 17(21) (2025) Article ID 3494 (15 pages); https://doi.org/10.3390/cancers17213494
- J. Jureczek, K. Kałwak and P. Dzięgiel, Antibody-based immunotherapies for the treatment of hematologic malignancies, Cancers 16(24) (2024) Article ID 4181 (24 pages); https://doi.org/10.3390/cancers16244181
- S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini, M. V. Mateos, S. Kumar, J. Hillengass, E. Kastritis, P. Richardson, F. Landgren, B. Durie, R. A. Kyle, and International Myeloma Working Group, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Blood 131(1) (2018) 13–20; https://doi.org/10.1182/blood-2017-06-740944
- M. Minnix, V. Adhikarla, E. Caserta, E. Poku, R. Shively and F. Pichiorri, Comparison of CD38- targeted α- versus β-radionuclide therapy of disseminated multiple myeloma in an animal model, J. Nucl. Med. 62 (2021) 795–801; https://doi.org/10.2967/jnumed.120.251983
- W. Dawicki, K. J. Allen, R. Jiao, M. E. Malo, M. Helal, M. S. Berger D. L. Ludwig and E. Dadachova, Daratumumab-²²⁵Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors, Oncoimmunology 8(8) (2019) Article ID 1607673 (9 pages); https://doi.org/10.1080/2162402X.2019.1607673
- I. Quelven, J. Monteil, M. Sage, A. Saidi, J. Mounier, A. Bayout, J.Garrier, M. Cogne and S. Du-rand-Panteixal, ²¹²Pb α-radioimmunotherapy targeting CD38 in multiple myeloma: A preclinical study, J. Nucl. Med. 61(7) (2020) 1058–1065; https://doi.org/10.2967/jnumed.119.239491
- S. Li, C. G. England, E. B. Ehlerding, C. J. Kutyreff, J. W. Engle, D. Jiang and W. Cai, ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using ⁶⁴Cu-labeled daratumumab, Am. J. Transl. Res. 11(9) (2019) 6007–6015.
- E. Caserta, J. Chea, M. Minnix, E. K. Poku, D. Viola, S. Vonderfecht, P. Yazaki, D. Crow, J. Khalife, J. F. Sanchez, J. M. Palmer, S. Hui, N. Carlesso, J. Keats, Y. Kim, R. Buettner, G. Marcucci, S. Rosen, J. Shively, D. Colcher, A. Krishnan and F. Pichiorri, Copper-64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma, Blood 131(7) (2018) 741–745; https://doi.org/10.1182/blood-2017-09-807263
- A. F. Viana and E. Cannarozzo, Theranostics explained: A personalized approach to cancer care, J. Nucl. Med. 67(4) (2026) 494–495; https://doi.org/10.2967/jnumed.125.271895
- L. Kang, C. Li, Z. T. Rosenkrans, N. Huo, Z. Chen, E. B. Ehlerding, Y. Huo, C. A. Ferreira, T. E. Barn-hart, J. W. Engle, R. Wang, D. Jiang, X. Xu and W. Cai, CD38-targeted theranostics of lymphoma with ⁸⁹Zr/¹⁷⁷Lu-labeled daratumumab, Adv. Sci. 8 (2021) Article ID 2001879 (13 pages); https://doi.org/10.1002/advs.202001879
- M. Sterjova, P. Džodić, P. Makreski, J. Živković and E. Janevik-Ivanovska, Electrophoresis and Raman spectroscopy characterization of integrity and secondary structure of p-SCN-Bn-DTPA-and p-SCN-Bn-1B4M-DTPA-conjugated trastuzumab, Farmacia 67(4) (2019) 621–626; https://doi.org/10.31925/farmacia.2019.4.10
- M. Sterjova, P. Džodić, P. Makreski, A. Duatti, M. Risteski and E. Janevik-Ivanovska, Vibrational spectroscopy as a tool for examination to the secondary structure of metal-labeled trastuzumab immunoconjugates, J. Radioanal. Nucl. Chem. 320 (2019) 209–218; https://doi.org/10.1007/s10967-019-06450-8
- U. Karczmarczyk, A. Sawicka, P. Garnuszek, M. Maurin and W. Wojdowska, Does the number of bifunctional chelators conjugated to a mAb affect the biological activity of its radio-labeled counterpart? Discussion using the example of mAb against CD-20 labeled with ⁹⁰Y or ¹⁷⁷Lu, J. Med. Chem. 65(9) (2022) 6419–6430; https://doi.org/10.1021/acs.jmedchem.1c02044
- G. Giannini, F. M. Milazzo, G. Battistuzzi, M. Lanza, D. Pirolli, S. Carradori and R. De Santis, Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumours, Bioorg. Med. Chem. 27(15) (2019) 3248–3253; https://doi.org/10.1016/j.bmc.2019.05.047
- J. A. Delage, A. Faivre-Chauvet, J. Barbet, J. K. Fierle, N. Schaefer, G. Coukos, D. Viertl, S. M. Dunn, S. Gnesin and J. O. Prior, Impact of DOTA conjugation on pharmacokinetics and immunoreactivity of [¹⁷⁷Lu]Lu-1C1m-Fc, an anti TEM-1 fusion protein antibody in a TEM-1 positive tumor mouse model, Pharmaceutics 13(1) (2021) Article ID 96 (19 pages); https://doi.org/10.3390/pharmaceutics13010096
- P. Matejtschuk, C. Bird, E. Ezeajughi, K. MacLellan-Gibson and M. Wadhwa, Impact of formulation choices on the freeze-drying of an interleukin-6 reference material, Front. Mol. Biosci. 9 (2022) Article ID 868460 (9 pages); https://doi.org/10.3389/fmolb.2022.868460
- Y. Cheng, H. T. Duong, Q. Hu, M. Shameem and X. C. Tang, Practical advice in the development of a lyophilized protein drug product, Antibody Ther. 8(1) (2025) 13–25; https://doi.org/10.1093/abt/tbae030
- T. T. Mutukuri, J. Ling, Y. Du, Y. Su and Q. T. Zhou, Effect of buffer salts on physical stability of lyophilized and spray-dried protein formulations containing bovine serum albumin and trehalose, Pharm. Res. 40(6) (2023) 1355–1371; https://doi.org/10.1007/s11095-022-03318-7
- M. Bjelošević and P. Ahlin Grabnar, Effects of monoclonal-antibody concentration and type of bulking agent on critical quality attributes of lyophilisates, J. Drug Deliv. Sci. Technol. 63 (2021) Article ID 102510; https://doi.org/10.1016/j.jddst.2021.102510
- United States Pharmacopeia, USP <922> Water Activity: A Better Approach for Lyo Moisture Determination – Applications Enabled by Rapid Non-destructive Headspace Moisture Analysis of Freeze-dried Product, USP, Rockville 2018; https://www.uspnf.com/notices/922-water-activity; last access date January 10, 2026
- J. Horn, J. Schanda and W. Friess, Impact of fast and conservative freeze-drying on product quality of protein-mannitol-sucrose-glycerol lyophilizates, Eur. J. Pharm. Biopharm. 127 (2018) 342–354; https://doi.org/10.1016/j.ejpb.2018.03.003
- L. Knoll, J. Thiesen, M. D. Klassen, L. M. Reinders, J. Türck and I. Kraemer, In-use stability of ready--to-administer daratumumab subcutaneous injection solution in plastic syringes, Eur. J. Hosp. Pharm. 32 (2025) 154–161; https://doi.org/10.1136/ejhpharm-2023-003883
- H. Godzo, O. Gigopulu, J. Acevska, N. Geskovski, A. P. Panovska, B. Acevski, F. Dimoska, M. Nuneva and K. Brezovska, Application of ATR-FTIR as a screening method for analysis of biopharmaceutical preparations containing trastuzumab, Maced. Pharm. Bull. 69 (Suppl. S1) (2023) 253–254; https://doi.org/10.33320/maced.pharm.bull.2023.69.03.124
Language: English
Accepted on: May 4, 2026
Published on: May 27, 2026
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Paulina Apostolova, Marija Atanasova Lazareva, Katarina Davalieva, Marija Arev, Dino Karpicarov, Petre Makreski, Irena Slaveska Spirevska, Ivana Mitrevska, Aleksandar Dimovski, Sanja Vranješ-Đurić, Emilija Janevik-Ivanovska, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.